Telo Genomics Corp
XTSX:TELO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Telo Genomics Corp
Other Items
Telo Genomics Corp
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Telo Genomics Corp
XTSX:TELO
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Other Items
-$32.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Other Items
$218.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
35%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Other Items
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Other Items
-$23.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Telo Genomics Corp
Glance View
Telo Genomics Corp. is a biotech company that is developing the most comprehensive telomere analysis platform in the industry, with powerful diagnostic and prognostic applications. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for numerous diseases that display genomic instability. Its lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. The firm's TeloView software consists of two parts, analytical software and a corresponding report designed for clinical decision making. TeloView utilizes the three-dimensional analysis of approximately six parameters generated from the telomeres of a single cell. Its TeloView software generates a report for the clinician that contains information, including the stage of a given disease, its rate of progression and how it responds to therapy. Its solutions include liquid biopsies and related technologies in oncology and neurological diseases.
